• Leading Biotechnology Innovator Specializing in AI Chatbot Solutions for Early Drug Discovery, Infectious Disease and Neurodegenerative Disease Research.
• Focus on Developing Therapeutic Solutions by Leveraging Human Immune-B Cells for a Cutting-Edge Approach to Highly Effective Treatments.
• Strategic Investment Plan Demonstrating Commitment to Advancing Technological Capabilities and Expanding Reach in the AI Sector.
• Launch of Sutra (TM), a Game-Changing AI Platform for Drug Discovery and Infectious Disease Research.
• Strategic Investment Target Adnexus Biotechnologies Merges with Sanctum Therapeutics to Obtain Breakthrough HIV and SARS-CoV-2 Treatments.
• AI Platform Confirmed Decades of Work and Added New Targets for Monoclonal Antibodies with Independent Validation of Their Potential from Collaborators.
• Growing IP Portfolio Including Patents, Trademarks and Trade Secrets.
• With a Database of 19 Viruses, the Sutra™ AI Platform Can Predict and Help Prevent Future Pandemics.
• Harnessing the Power of AI to Revolutionize Drug Repurposing, Offering a Cost-Effective Alternative to Developing New Drugs from the Ground Up.
1606 Corp. (OTC: CBDW) stands at the forefront of technological innovation, particularly in AI Chatbots. The CBDW mission is to revolutionize customer service, addressing the most significant challenges faced by consumers in the digital marketplace. CBDW is dedicated to transforming the IR industry through cutting-edge AI centric solutions, ensuring a seamless and efficient customer experience.
CBDW is a leading innovator in biotechnology, specializing in AI-driven solutions for early drug discovery, infectious disease, and neurodegenerative disease research. CBDW proprietary methods focus on developing therapeutic solutions by leveraging human immune-B cells, offering a cutting-edge approach to creating highly effective treatments.
CBDW Generative AI Chatbots can provide instant, round-the-clock support, guiding potential investors through the company. Queries about dosage, usage, legality, while offering personalized recommendations based on individual preferences. Moreover, CBDW chatbots can handle multiple interactions simultaneously, ensuring no potential or existing investor feels neglected due to long response times. They also collect valuable data on investor preferences and behaviors, allowing companies to tailor their communication strategies more effectively. In the investor relations industry, where transparency and timely information are paramount, CBDW chatbots can provide up-to-date details on earnings reports, stock performance and company news. This immediate access to information builds confidence with investors, encouraging them to make informed decisions.
The global artificial intelligence market has seen remarkable growth, valued at $428 billion in 2022 and projected to reach $2.25 trillion by 2030. With a compound annual growth rate (CAGR) ranging from 33.2% to 38.1%, AI's global impact is undeniable, with as many as 97 million individuals expected to work in the AI sector by 2025, according to fortunebusinessinsights.com
CBDW Target for Strategic Investment Adnexus Biotechnologies Merges with Sanctum Therapeutics to Obtain Breakthrough HIV and SARS-CoV-2 Treatments
On November 12th CBDW acquisition target Adnexus Biotechnologies Inc. is revealed completion of a merger agreement to acquire Sanctum Therapeutics core technology assets for treating HIV and SARS-CoV-2. This merger will combine the two biotechnology companies' significant resources and expertise. The combination of resources and expertise significantly enhance the research capabilities of CBDW HIV and SARS-CoV-2 research.
Adnexus Biotechnologies Inc. is poised to revolutionize its HIV and infectious disease portfolio with the acquisition of Sanctum Therapeutics' leading-edge assets. This strategic merger combines Adnexus's state-of-the-art AI-driven drug discovery platform with Sanctum's innovative long-acting HIV capsid inhibitor and Adnexus's short-acting anti-HIV monoclonal antibodies. Together, these therapies offer a potent, dual-action approach that enhances treatment efficacy, reduces the risk of viral resistance, and provides a promising new option for HIV patients.
The acquisition further strengthens the CBDW position in the rapidly growing market for HIV treatments, while also expanding its pipeline of drug candidates targeting antimicrobial-resistant infections and other infectious diseases. With Sanctum's advanced inhibitors and expertise in navigating the FDA regulatory landscape, CBDW will be uniquely positioned to accelerate the development of high-impact therapies.
Adnexus has recently executed a Letter of Intent with the CBDW for a strategic investment by the Company for 5% of Adnexus. The LOI terminates on November 27, 2024 and has an option to extend.
Unveils Sutra (TM) is a Game-Changing AI Platform for Drug Discovery and Infectious Disease Research
On October 1st CBDW announced its new AI Empowered Drug Discovery Platform, Sutra™.
The CBDW Sutra™ AI platform has not just confirmed decades of work, but also added new targets for monoclonal antibodies within weeks, receiving independent validation of their potential from collaborators. CBDW AI algorithms have identified several promising drug candidates. CBDW has identified a target in the mitochondrial metabolism that has a role in oncology. CBDW then adds them to an ever-growing IP portfolio, including patents, trademarks, and trade secrets, enhancing its competitive advantage and potential for future revenue. The success and validation of the CBDW Sutra™ AI platform for AI-discovered drugs are testaments to its capabilities and the future it promises.
CBDW is dedicated to pushing the boundaries of drug discovery with its AI Drug Discovery (AIDD) player, Sutra™. With the CBDW AI-powered structure prediction algorithms, this platform has the potential to revolutionize drug discovery. It can design small molecules, optimize the design of antibodies and other proteins, and even repurpose drug molecules.
With a database of 19 viruses, the CBDW Sutra™ AI platform can predict and help prevent future pandemics. With access to a curated library of 8 million molecules, the CBDW platform makes possible the discovery of new drugs that precisely target neutralizable epitopes on viruses to enhance the potency and efficacy of existing therapies. The CBDW Sutra™ team's unwavering dedication to leveraging microbiome samples to identify new biomarkers for neurodegenerative diseases instills hope for future medical breakthroughs.
CBDW harnesses the power of AI to revolutionize drug repurposing, offering a cost-effective alternative to developing new drugs from the ground up. Drug repurposing involves identifying potential new applications for existing compounds, which can be time-consuming and labor-intensive. However, AI algorithms can analyze existing drug databases and identify potential new applications for these compounds in a fraction of the time, making it a game-changer in the pharmaceutical industry. CBDW is exploring synergizing AI with suitable linkers between antibodies and drugs to promote multi-drug combinations. This approach will bring new therapeutics to market with more substantial impacts than combination therapies and address unmet medical needs, expediting drug discovery and regulatory approvals.
For more information on $CBDW visit: https://www.adnexusbiotech.com and https://cbdw.ai/
• Please verify and update the Website under media contact details.
Media Contact
Company Name: 1606 Corp.
Contact Person: Gaurav Chandra, CEO
Email: Send Email
Phone: (602) 481-1544
Address:2425 East Camelback Road Suite 150
City: Phoenix
State: AZ 8501
Country: United States
Website: https://www.adnexusbiotech.com
